Use of E-health Based Exercise Intervention After COVID-19

Effect E-health Based Exercise Intervention After COVID-19

Reduced subjective and objective functional capacity performance are reported after COVID-19 in a large proportion of subjects. The aim of this study is to examine the feasibility and effect of using an e-health tool for guidance and tracking of exercise training in a general population of adults previously infected by COVID-19.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Behavioral: Exercise training using an e-health tool

Detailed Description

Both hospitalized and non-hospitalized persons who have undergone extensive multi-disciplinary rehabilitation programs report significantly improved physical function after rehabilitation. Exercise training may be the key intervention to improve fitness and subjective complaints such as fatigue, low physical fitness and dyspnea after COVID-19 infection. However, traditional group-based exercise training or self-training programs at fitness centers have been shut down during the pandemic, and home-based interventions are warranted. To overcome the limitations and costs of a fitness center/personal trainer-based intervention study, more knowledge on the effectiveness and efficacy of using an e-Health system to recruit, train and monitor participants after illness are needed.

• Study Type: Interventional
• Enrollment (Actual): 77
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Norway
  • Trondheim, Norway, 7006
    • Norwegian University of Science and Technology, Faculty of medicine, Department of circulation and medical imaging,

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 59 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Persons who have undergone COVID-19 disease
• People who struggle to be physically active enough as a result of corona disease
• People who experience reduced physical fitness as a result of corona disease

Exclusion Criteria:

-- more than 100 AQ per week (calculated from self-reported activity level)

• uncontrolled hypertension (high blood pressure) (over 200/110).
• symptomatic valve failure, hypertrophic cardiomyopathy, unstable angina, pulmonary
• hypertension, heart failure and/or severe rhythm disturbances
• cancer that makes participation impossible or exercise contraindicated. Considered individually in consultation with the attending physician.
• chronic contagious infectious diseases.
• Participates in other studies that are not compatible with participation in this project
• Post-exertional symptom exacerbation (PESE)/post-exertional malaise (PEM)/post-exertional neuroimmune exhaustion (PENE).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control group
Experimental: Supervised exercise	Behavioral: Exercise training using an e-health tool; Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Activity Quotient (AQ) equivalents per week Control: No follow-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibilty	Measured as acceptability and adherence	After 6 months intervention
Cardiorespiratory fitness	Peak oxygen uptake	After 6 months intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lung function	Spirometry	After 6 months intervention
Quality of life	Questionnaires (RAND-12)	After 6 months intervention

Collaborators and Investigators

• Sponsor: Norwegian University of Science and Technology
• Collaborators: University of Oslo
• Investigators: Principal Investigator: Dorthe Stensvold Stensvold, Dorthe Stensvold, Professor, NTNU

Study record dates

Study Major Dates

• Study Start (Actual): April 17, 2023
• Primary Completion (Actual): May 31, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: March 13, 2023
• First Submitted That Met QC Criteria: March 13, 2023
• First Posted (Actual): March 15, 2023

Study Record Updates

• Last Update Posted (Actual): January 5, 2026
• Last Update Submitted That Met QC Criteria: December 30, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19
• Other Study ID Numbers: 479316

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No